Elite Pharmaceuticals Inc. (ELTP)
OTCQB OTCQB Primary 
ELTP vs. DERM: Which Specialty Pharmaceutical Stock Is the Better Buy?
Elite Pharmaceuticals and Journey Medical follow different growth paths, but which looks more compelling now? Let's dive in.
Elite Pharmaceuticals Stock Plunges Post Q1 Earnings, Revenues Fall Y/Y
ELTP's first-quarter fiscal 2027 revenues decline as generic competition and lower pricing offset higher volumes, while pipeline development remains a growth focus.
Elite Pharmaceuticals, Inc. (ELTP) Q1 2027 Earnings Call Transcript
Elite Pharmaceuticals, Inc. (ELTP) Q1 2027 Earnings Call Transcript
Elite Pharmaceuticals Q1 Earnings Call Highlights
Elite Pharmaceuticals OTCMKTS: ELTP reported first-quarter fiscal 2027 revenue of $32.4 million and operating profit of $7.5 million, with Chief Financial Officer Carter Ward describing both measures as steady and consistent with the preceding three quarters.
ELTP vs. CPIX: Which Pharma Stock Is the Better Buy Right Now?
Elite Pharmaceuticals and Cumberland Pharmaceuticals follow different growth paths, but which looks more compelling now? Let's dive in.
Elite Pharmaceuticals Stock Slips Despite Record Fiscal 2026 Earnings
ELTP delivers record fiscal 2026 results, with stronger profits, improved cash and pipeline progress supporting its expanding generics platform.
Elite Pharmaceuticals, Inc. (ELTP) Q4 2026 Earnings Call Transcript
Elite Pharmaceuticals, Inc. (ELTP) Q4 2026 Earnings Call Transcript
Elite Pharmaceuticals Stock Dips Post Q3 Earnings Despite Revenue Jump
ELTP reports surging revenue and profit in third-quarter fiscal 2026, but margin pressure and M&A ambitions steal the spotlight.
ELTP Stock Declines Despite Solid Q2 Earnings and Revenue Performance
Elite Pharmaceuticals delivers record second-quarter fiscal 2026 earnings as lisdexamfetamine sales surged, though margins faced competitive pressure.
Elite Pharmaceuticals, Inc. (ELTP) Q2 2026 Earnings Call Transcript
Elite Pharmaceuticals, Inc. (OTCQB:ELTP) Q2 2026 Earnings Call November 17, 2025 11:30 AM EST Company Participants Nasrat Hakim - Chairman, CEO & President Carter Ward - CFO, Secretary & Treasurer Presentation Operator Good morning, ladies and gentlemen, and welcome to the Elite Pharmaceuticals Second Quarter of Fiscal Year 2026 Conference Call. [Operator Instructions] Before management begins speaking, the conference has the following statement.
ELTP Stock Gains Following Q1 Earnings Showing Strong Revenue Growth
Elite Pharmaceuticals reports strong first-quarter fiscal 2026 results with rising direct sales, higher-margin products and expanding gross profit.
2 Outperform Rated Small Caps with Recent Pull-backs
ELTP and TSSI are growth stories with recent material pull-backs.
